A strange brew of Tamiflu and Swine flu

SPICY IP:

Image taken from here 
Everything surrounding the Swine Flu seems to be quite mysterious. Starting with allegations that the virus itself may have been a man-made product that got loose, to the scare being exaggerated to sell more drugs for it and put more money in Donald Rumsfield’s pockets, the events and scenarios existing around this disease are proving to be quite interesting. Yet there are more interesting  ingredients involved in this strange soup.
Oseltamivir is one of the best drugs currently available used to fight Swine flu. While Gilead has patented this in other countries under the name Tamiflu, their patent application was struck down in India in March 2009 for [a] lack of inventive step, [b] failure to comply with S.3(d) and [c] failure to sufficiently disclose the invention claimed. This technically clears the path for Indian generic companies to start producing the drug. However, first, as described here, the government created an artificial monopoly of sorts by directly procuring and supplying the drug to hospitals from Hoffman-La Roche and its Indian licensee Hetero Drugs. (Gilead has given an exclusive license to Roche for Tamiflu.). Cipla, which had opposed the Tamiflu patent, naturally weren’t very happy about this and questioned the government about this. 
This problem was later sorted out and retail sales of Oseltamivir were allowed. There are currently six private sector pharmaceutical companies who are producing the drug. Of these, Hetero Drugs, Cipla, Ranbaxy and Strides Acrolab are able to indigenously produce Oseltamivir from its raw material. Now, recently, the Parliamentary Standing Commission on Chemicals and Fertilizers has said that as it is a life saving drug, Central Public Sector Undertakings (CPSUs) ought to manufacture the drug as well. To this, the Department of Pharmaceuticals (DoP) has given two reasons as to why